MIV Therapeutics to Present Advanced Biocompatible Stent-Coating Technology at International Biomaterials Conference; Senior Scientist Invited to Review Data at 19th International Symposium on Ceramics in Medicine in China.

ATLANTA -- MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, is scheduled present the highly encouraging development progress of the Company's Hydroxyapatite (HAp) coatings for coronary stents and other devices at the 19th International Symposium on Ceramics in Medicine conference in Chengdu, China.

Dr. Quanzu Yang, PhD, from MIVT research partner University of British Columbia, will addressthe international body of biomaterials scientists and industry leaders to discuss recent research developments. Dr. Yang will discuss data regarding the long-term biocompatibility and other advantages of the Company's patented technology for deposition of HAp coatings and encapsulation of drugs in the HAp coatings.

"The microporous ultra-thin HAp coating with a potential for drug elution shows excellent promise for long-term biocompatibility, and makes an attractive candidate for next-generation stent coating," said Dr. Yang, "It's an honor to present our work with HAp and I look forward to discussing these and other findings with our colleagues in China. Our newest, polymer-free technology for drug encapsulation in HAp coatings shows the potential to revolutionize the industry of medical devices with drug delivery capabilities"

The conference will focus on bioceramics, such as calcium phosphates and hydroxyapatite technology; an indispensable biomaterials in clinical practice. The annual conference will concentrate on new challenges being faced in the bioceramics industry from the progress of modern medicine. It will provide a multi-disciplinary platform for Biomaterials, Scientists, Researchers, Engineers, Manufacturers, Dentists and Surgeons to share their latest achievements and encourage important discussion for next breakthroughs in the field.

Based on bioceramics technology, MIVT's HAp coatings are designed to substantially improve the safety and long-term performance of vascular stents because they do not trigger adverse reactions of the body's immune system commonly associated with existing stent technology. Such complications include inflammation, creation of thrombus (blood clots) and, importantly, re-narrowing of arteries due to endothelial tissue re-growth inside blood vessels in the area of newly implanted stents.

During the presentation, MIVT will also report on the progress of development of novel HAp coatings for implants, such as hip or knee implants, developed under the collaborative research and development program between the University of British Columbia and MIVT. Research has been focused on wet chemical technologies for ultra-thin and micro-thin calcium-phosphate based bio-ceramic films. The ultra-thin films have been designated as a surface modification of metallic implants, where the micro-thin films are evaluated as a potential vehicle for drug delivery purposes for implantable medical devices.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.